2020
DOI: 10.1186/s13058-020-01258-x
|View full text |Cite
|
Sign up to set email alerts
|

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Abstract: Background: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptorpositive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Methods: Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone rece… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 52 publications
2
7
0
Order By: Relevance
“…In addition, the application of bevacizumab tended to result in therapy discontinuation due to treatment-related toxicity but did not reach a significant difference. The profile and frequencies of the bevacizumab-related AEs in this study were similar to those reported in other studies [ 31 , 32 , 33 ]. For example, Vaklavas et al [ 33 ] assessed the toxicity of bevacizumab.…”
Section: Discussionsupporting
confidence: 89%
“…In addition, the application of bevacizumab tended to result in therapy discontinuation due to treatment-related toxicity but did not reach a significant difference. The profile and frequencies of the bevacizumab-related AEs in this study were similar to those reported in other studies [ 31 , 32 , 33 ]. For example, Vaklavas et al [ 33 ] assessed the toxicity of bevacizumab.…”
Section: Discussionsupporting
confidence: 89%
“…Of the 4 tumors that were upstaged, 3 were invasive lobular and 1 invasive mammary carcinomas. Given the diffuse growth pattern and lack of desmoplastic reaction in invasive lobular carcinoma, this nding may re ect underestimation of the extent of the original disease rather than interval tumor growth [10]. Representative radiographic responses are shown in Fig.…”
Section: Safety and Tolerabilitymentioning
confidence: 99%
“…Exploiting therapeutically the interplay between angiogenesis and estrogen receptor (ER), we have shown in 2 separate clinical trials that the addition of bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), to letrozole, leads to pCR rates (11-12%) comparable to preoperative chemotherapy [3,9,10]. The addition of mammalian Target of Rapamycin (mTOR) inhibitor to hormonal therapy reverses endocrine resistance and enhances the e cacy of hormonal agents [11][12][13][14].…”
Section: Introductionmentioning
confidence: 99%
“…Population Outcome High serum VEGF-A [35] HER2-/HR+BC pCR High serum VEGF-C [35] TNBC pCR Amplifications of VEGFA and TMEM100(an ALK1 receptor signaling-dependent gene essential for vasculogenesis [36] HER2-BC pCR A set of five small RNAs associated with the regulation of VEGF pathway [18] HER2-/HR+ BC pCR Soluble carbonic anhydrase IX (sCAIX), upregulated in hypoxic conditions [37] HER2-BC pCR, DFS…”
Section: Molecular Characteristicmentioning
confidence: 99%